Immunization with recombinant rabies virus expressing Interleukin-18 exhibits enhanced immunogenicity and protection in mice
PDF | HTML | How to cite
Metrics: PDF 1181 views | HTML 2505 views | ?
Weiwei Gai1,2,*, Wenwen Zheng1,*, Chong Wang3,*, Gary Wong4, Yanyan Song1 and Xuexing Zheng2
1College of Veterinary Medicine, Jilin University, Changchun, China
2School of Public Health, Shandong University, Jinan, China
3State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China
4CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
*These authors have contributed equally to this work
Xuexing Zheng, email: [email protected]
Keywords: rabies virus, IL-18, immune responses, vaccine, antibody titer
Received: March 03, 2017 Accepted: July 18, 2017 Published: September 16, 2017
Several studies have shown that interleukin-18 (IL-18) plays an important role in both innate and adaptive immune responses. In this study, we investigated the pathogenicity and immunogenicity of recombinant rabies virus expressing IL-18 (rHEP-IL18). Experimental results showed that Institute of Cancer Research (ICR) mice that received a single intramuscular immunization with rHEP-IL18 elicited the highest titers of serum neutralizing antibodies and the strongest cell-mediated immune responses to prevent the development of rabies disease, compared with immunization with the parent virus HEP-Flury. Mice inoculated with rHEP-IL18 developed significantly higher IFN-γ responses, increased percentages of CD4+ and CD8+ T-lymphocytes compared to HEP-Flury. Flow cytometry results show that rHEP-IL18 recruited more activated T- and B-cells in lymph nodes or peripheral blood, which is beneficial for virus clearance in the early stages of infection. A higher percentage of mice immunized with rHEP-IL18 survived wild-type rabies virus (RABV) challenge, compared to HEP-Flury mice. Our results show that rHEP-IL18 is promising as a novel vaccine for RABV prevention and control.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.